Nothing said here yet.
to join the conversation.
GSK (LSE:GSK) received accelerated FDA approval for Jemperli as the first immunotherapy for certain rectal cancer patients. The approval covers a genetically defined group of rectal cancer cases where Jemperli offers a non surgical treatment option.
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
GSK (LSE:GSK) has released third quarter figures that present a mixed picture. Sales reached £8,887 million, while net income declined to £1,543 million compared with £2,013 million a year earlier.
GSK (NYSE:GSK) reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit increased 5%, while core earnings per share rose 1%.
Revenue from GSK's vaccines came up short Wednesday, including the drugmaker's household name shot, Shingrix.
British pharma company one of biggest fallers on FTSE 100 despite better than expected financial results Business live – latest updates Shares in GSK slid on Wednesday despite the UK drugmaker reporting better than expected financial results, as investors…
GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
GSK beats earnings estimates handily, but suffers soft vaccine sales. The biopharma is moving quickly to bring new medicines to market faster.
GSK stock toppled early Wednesday after the company's third-quarter vaccine sales fell short, outshining a solid topline.
British pharma company reports declining profits amid concerns over looming patent loss for blockbuster HIV drug Business live – latest updates Shares in GSK slid on Wednesday despite the UK drugmaker reporting better than expected financial results, as…
British pharma company reports declining profits amid weaker vaccine sales and looming patent loss for blockbuster HIV drug Business live – latest updates Shares in GSK slid on Wednesday despite the UK drugmaker reporting better than expected financial…
Glaxo (GSK) delivered earnings and revenue surprises of +5.00% and +1.24%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?